At #EAU25, Dr. Ricardo Almeida Magana (UCL, London) presented compelling data from the NeuroSAFE PROOF trial, a multicenter, randomized phase 3 study evaluating the role of intraoperative frozen section analysis (NeuroSAFE) during robot-assisted radical prostatectomy (RARP) for localized prostate cancer.
In this head-to-head comparison of NeuroSAFE-guided RARP vs standard RARP, the results were clear:
Erectile function recovery at 12 months was nearly twice as high in the NeuroSAFE group
No compromise in oncological safety
Improved nerve-sparing decisions and quality of life
This trial marks a significant advancement in prostate cancer surgery, demonstrating that functional preservation and cancer control can go hand in hand when supported by precise intraoperative decision-making.
Congratulations to Dr. Almeida-Magana and the international trial team for delivering high-impact data that could shape future surgical standards.
For more details: https://lnkd.in/dVn6z-Cw
